Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees

The Generic Pharmaceutical Association is balking at continuing to negotiate the design of a biosimilar user fee program that is independent of other user fees and has its own baseline appropriations trigger.